Virtual Library

Start Your Search

K. Suina



Author of

  • +

    P1.03 - Chemotherapy/Targeted Therapy (ID 689)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P1.03-006 - Clinicopathological Features and Poor Outcome for ALK Inhibitors of Squamous Cell Lung Cancer with ALK-Rearrangement (ID 8738)

      09:30 - 16:00  |  Author(s): K. Suina

      • Abstract
      • Slides

      Background:
      Anaplastic lymphoma kinase (ALK)-rearrangements are mainly encountered in 5% of adenocarcinomas lung cancer (Ad-LC) patients and anti-ALK targeted therapy dramatically improves therapeutic responses. The prevalence of ALK rearrangement in squamous cell lung carcinomas (Sq-LC) is extremely rare and thus, clinicopathological features and clinical outcomes for ALK inhibitors of ALK-rearranged Sq-LC were still unknown. Accordingly, in this study, we compared clinical features and clinical outcomes in patients with Sq-LC and Ad-LC.

      Method:
      We retrospectively analysed the clinical features of five patients with ALK-rearranged Sq-LCs including two ALK-rearranged adenosquamous cell lung carcinomas (AdSq-LC) and compared the results with ALK-rearranged Ad-LC. We also evaluated representative cases of both responder and nonresponder to ALK inhibitors.

      Result:
      The prevalence of ALK rearrangement in Sq-LCs was 1.36%. The population in ALK rearrangement NSCLC with smoking history was higher in ALK-rearranged Sq-LC than in ALK-rearranged Ad-LCs (80.0% and 68.0%). Progression-free survival (PFS) after initial treatment with the ALK inhibitor crizotinib was significantly shorter in ALK-rearranged Sq-LC than in ALK-rearranged Ad-LC (6.4±4.7 months and 13.4±12.8 months: p=0.033). Notably, two ALK fluorescence in situ hybridization (FISH)-positive/immunohistochemistry-negative cases did not respond to crizotinb, and PFS following alectinib treatment of ALK-rearranged Sq-LC was short (p = 0.045). The responder to ceritinib showed the presence of the L1196M mutation, which causes other ALK inhibitor resistance, by rebiopsy and successes to maintain CR response, even if detected off-target resistance marker of both EGFR and vimentin, a marker of EMT, for ALK inhibitors. However, the nonresponder did not respond to all ALK inhibitors, despite the presence of ALK FISH-positive circulating tumor cells and circulating free DNA without the mutation for ALK inhibitors resistance by liquid-biopsy.

      Conclusion:
      ALK-rearranged Sq-LC was associated with poor outcomes in ALK inhibitor-treated patients, suggesting that complexity of resistance mechanisms including off-target mechanisms for ALK inhibitors may exist. Oncologists should be aware of the possibility of ALK-rearranged Sq-LC based on clinicopathological features and plan the next therapeutic strategy by as much of re-biopsy accordingly to improve clinical outcomes.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.